Key facts
- This page summarizes DeLyle W. Bloomquist's Form 4 filing for PDS Biotechnology Corp (PDSB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2021, 16:30.
DeLyle W. Bloomquist - 16 Jun 2021 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)
- Reporting relationship
- Resigned as a Director on June 17, 2021.
- Issuer ticker
- PDSB
- Reported as of
- 16 Jun 2021
- Net transaction value
- +$116,568
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2021, 16:30:48 UTC
- Prior SEC filing
- 20 May 2021
- Next SEC filing
- 19 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Hillary Yegen, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
DeLyle W. Bloomquist filed Form 4 for PDS Biotechnology Corp (PDSB) on 21 Jun 2021.
Change
- Previous filing in this sequence was filed on 20 May 2021.
- Current net transaction value: +$116,568.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PDSB
transaction
Common Stock
Options Exercise
- Transaction value
- $17,790
- Shares
- +2,970
- Change %
- +1.6%
- Price
- $5.99
- Shares after
- 183,888
- Date
- 16 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
PDSB
transaction
Common Stock
Purchase
- Transaction value
- $98,778
- Shares
- +10,000
- Change %
- +5.4%
- Price
- $9.88
- Shares after
- 193,888
- Date
- 16 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
PDSB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 605,023
- Date
- 16 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PDSB
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,970
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 6,030
- Date
- 16 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,970
- Exercise price
- $5.99
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
DeLyle W. Bloomquist is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The shares reported on this Form 4 are subject to a lock-up agreement between Mr. Bloomquist and Cantor Fitzgerald & Co. in connection with a public offering of common shares by the Issuer which closed on June 17, 2021.
Footnote F2
Represents shares of Common Stock of the Issuer that Mr. Bloomquist purchased in the open market. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.85 to $9.90, inclusive.
Footnote F3
Mr. Bloomquist owns 80% of and is the manager of Asklepios Capital LLC and has voting and dispositive power with respect to these shares.
Footnote F4
One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022, subject in all respects to the option agreement governing the stock option grant.
SEC remarks
Resigned as a Director on June 17, 2021.